Literature DB >> 26661731

ApoA1, ApoJ and ApoE Plasma Levels and Genotype Frequencies in Cerebral Amyloid Angiopathy.

Alex Montañola1, Sofía Fernández de Retana1, Antonio López-Rueda1, Cristina Merino-Zamorano1, Anna Penalba1, Paula Fernández-Álvarez2, David Rodríguez-Luna3, Ana Malagelada4, Francesc Pujadas4, Joan Montaner1,3, Mar Hernández-Guillamon5.   

Abstract

The involvement of apolipoproteins, such as the ApoE4 isoform, in Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA) highlights the fact that certain lipid carriers may participate in soluble β-amyloid (Aβ) transport. Our general aim was to characterize the soluble levels of the apolipoproteins apoE, apoA1 and apoJ/clusterin and their genotype status in patients with CAA. We analyzed the genotypes frequency of APOA1 (rs5069, rs670), CLU (rs11136000, rs1532278, rs7012010, rs9331888) and APOE (rs429358, rs7412) in a cohort of patients with CAA-associated intracerebral hemorrhage (ICH) (n = 59) and compared the results with those from hypertension-associated ICH (n = 42), AD patients (n = 73) and controls (n = 88). In a subgroup of patients, we also determined the plasma concentrations of apoE, apoA1 and apoJ/clusterin. We found increased plasma apoJ/clusterin levels in CAA patients compared to AD patients or controls after adjusting for sex and age (CAA vs. controls, p = 0.033; CAA vs. AD, p = 0.013). ApoA1 levels were not altered between groups, although a strong correlation was observed between plasma Aβ(1-40) and apoA1 among CAA patients (r = 0.583, p = 0.007). Regarding plasma apoE concentration, a robust association between circulating levels and genotype status was confirmed (p < 0.001). Whereas the APOE4 frequency was higher in AD (p < 0.001) and CAA (p = 0.013), the APOA1 and CLU genotypes were not different among groups. In the CAA cohort, the risk-linked CLU variant (C) rs11136000 was associated with white matter hyperintensities (p = 0.045) and the presence of lobar microbleeds (p = 0.023) on MRI. In summary, our findings suggest that apoA1 may act as a physiological transporter of Aβ(1-40) and that apoJ/clusterin appears to be a chaperone related to distinctive lesions in CAA brains.

Entities:  

Keywords:  APOA1; APOE; APOJ; Alzheimer’s disease; CLU; Cerebral Amyloid Angiopathy; Clusterin; apoA1; apoE; apoJ

Mesh:

Substances:

Year:  2015        PMID: 26661731     DOI: 10.1007/s12017-015-8381-7

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  59 in total

1.  Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging.

Authors:  V B Gupta; S M Laws; V L Villemagne; D Ames; A I Bush; K A Ellis; J K Lui; C Masters; C C Rowe; C Szoeke; K Taddei; R N Martins
Journal:  Neurology       Date:  2011-03-22       Impact factor: 9.910

2.  improving interrater agreement about brain microbleeds: development of the Brain Observer MicroBleed Scale (BOMBS).

Authors:  Charlotte Cordonnier; Gillian M Potter; Caroline A Jackson; Fergus Doubal; Sarah Keir; Cathie L M Sudlow; Joanna M Wardlaw; Rustam Al-Shahi Salman
Journal:  Stroke       Date:  2008-11-13       Impact factor: 7.914

3.  Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy.

Authors:  S M Greenberg; J P Vonsattel; A Z Segal; R I Chiu; A E Clatworthy; A Liao; B T Hyman; G W Rebeck
Journal:  Neurology       Date:  1998-04       Impact factor: 9.910

4.  The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma.

Authors:  A Koudinov; E Matsubara; B Frangione; J Ghiso
Journal:  Biochem Biophys Res Commun       Date:  1994-12-15       Impact factor: 3.575

5.  Plasma clusterin and the risk of Alzheimer disease.

Authors:  Elisabeth M C Schrijvers; Peter J Koudstaal; Albert Hofman; Monique M B Breteler
Journal:  JAMA       Date:  2011-04-06       Impact factor: 56.272

6.  Characterization of apolipoprotein J-Alzheimer's A beta interaction.

Authors:  E Matsubara; B Frangione; J Ghiso
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

7.  Amyloid beta binding proteins in vitro and in normal human cerebrospinal fluid.

Authors:  A Golabek; M A Marques; M Lalowski; T Wisniewski
Journal:  Neurosci Lett       Date:  1995-05-19       Impact factor: 3.046

8.  Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.

Authors:  Adam C Naj; Gyungah Jun; Gary W Beecham; Li-San Wang; Badri Narayan Vardarajan; Jacqueline Buros; Paul J Gallins; Joseph D Buxbaum; Gail P Jarvik; Paul K Crane; Eric B Larson; Thomas D Bird; Bradley F Boeve; Neill R Graff-Radford; Philip L De Jager; Denis Evans; Julie A Schneider; Minerva M Carrasquillo; Nilufer Ertekin-Taner; Steven G Younkin; Carlos Cruchaga; John S K Kauwe; Petra Nowotny; Patricia Kramer; John Hardy; Matthew J Huentelman; Amanda J Myers; Michael M Barmada; F Yesim Demirci; Clinton T Baldwin; Robert C Green; Ekaterina Rogaeva; Peter St George-Hyslop; Steven E Arnold; Robert Barber; Thomas Beach; Eileen H Bigio; James D Bowen; Adam Boxer; James R Burke; Nigel J Cairns; Chris S Carlson; Regina M Carney; Steven L Carroll; Helena C Chui; David G Clark; Jason Corneveaux; Carl W Cotman; Jeffrey L Cummings; Charles DeCarli; Steven T DeKosky; Ramon Diaz-Arrastia; Malcolm Dick; Dennis W Dickson; William G Ellis; Kelley M Faber; Kenneth B Fallon; Martin R Farlow; Steven Ferris; Matthew P Frosch; Douglas R Galasko; Mary Ganguli; Marla Gearing; Daniel H Geschwind; Bernardino Ghetti; John R Gilbert; Sid Gilman; Bruno Giordani; Jonathan D Glass; John H Growdon; Ronald L Hamilton; Lindy E Harrell; Elizabeth Head; Lawrence S Honig; Christine M Hulette; Bradley T Hyman; Gregory A Jicha; Lee-Way Jin; Nancy Johnson; Jason Karlawish; Anna Karydas; Jeffrey A Kaye; Ronald Kim; Edward H Koo; Neil W Kowall; James J Lah; Allan I Levey; Andrew P Lieberman; Oscar L Lopez; Wendy J Mack; Daniel C Marson; Frank Martiniuk; Deborah C Mash; Eliezer Masliah; Wayne C McCormick; Susan M McCurry; Andrew N McDavid; Ann C McKee; Marsel Mesulam; Bruce L Miller; Carol A Miller; Joshua W Miller; Joseph E Parisi; Daniel P Perl; Elaine Peskind; Ronald C Petersen; Wayne W Poon; Joseph F Quinn; Ruchita A Rajbhandary; Murray Raskind; Barry Reisberg; John M Ringman; Erik D Roberson; Roger N Rosenberg; Mary Sano; Lon S Schneider; William Seeley; Michael L Shelanski; Michael A Slifer; Charles D Smith; Joshua A Sonnen; Salvatore Spina; Robert A Stern; Rudolph E Tanzi; John Q Trojanowski; Juan C Troncoso; Vivianna M Van Deerlin; Harry V Vinters; Jean Paul Vonsattel; Sandra Weintraub; Kathleen A Welsh-Bohmer; Jennifer Williamson; Randall L Woltjer; Laura B Cantwell; Beth A Dombroski; Duane Beekly; Kathryn L Lunetta; Eden R Martin; M Ilyas Kamboh; Andrew J Saykin; Eric M Reiman; David A Bennett; John C Morris; Thomas J Montine; Alison M Goate; Deborah Blacker; Debby W Tsuang; Hakon Hakonarson; Walter A Kukull; Tatiana M Foroud; Jonathan L Haines; Richard Mayeux; Margaret A Pericak-Vance; Lindsay A Farrer; Gerard D Schellenberg
Journal:  Nat Genet       Date:  2011-04-03       Impact factor: 38.330

9.  Transthyretin Amyloidosis: Chaperone Concentration Changes and Increased Proteolysis in the Pathway to Disease.

Authors:  Gonçalo da Costa; Cristina Ribeiro-Silva; Raquel Ribeiro; Samuel Gilberto; Ricardo A Gomes; António Ferreira; Élia Mateus; Eduardo Barroso; Ana V Coelho; Ana Ponces Freire; Carlos Cordeiro
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

10.  No diagnostic value of plasma clusterin in Alzheimer's disease.

Authors:  Edina Silajdžić; Lennart Minthon; Maria Björkqvist; Oskar Hansson
Journal:  PLoS One       Date:  2012-11-28       Impact factor: 3.240

View more
  9 in total

1.  CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease.

Authors:  Júlia Faura; Alejandro Bustamante; Anna Penalba; Dolors Giralt; Alba Simats; Elena Martínez-Sáez; Daniel Alcolea; Juan Fortea; Alberto Lleó; Charlotte E Teunissen; Wiesje M van der Flier; Laura Ibañez; Oscar Harari; Carlos Cruchaga; Mar Hernández-Guillamón; Pilar Delgado; Joan Montaner
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

2.  Proteomics analysis identifies new markers associated with capillary cerebral amyloid angiopathy in Alzheimer's disease.

Authors:  David C Hondius; Kristel N Eigenhuis; Tjado H J Morrema; Roel C van der Schors; Pim van Nierop; Marianna Bugiani; Ka Wan Li; Jeroen J M Hoozemans; August B Smit; Annemieke J M Rozemuller
Journal:  Acta Neuropathol Commun       Date:  2018-06-04       Impact factor: 7.801

3.  Analyzing 74,248 Samples Confirms the Association Between CLU rs11136000 Polymorphism and Alzheimer's Disease in Caucasian But Not Chinese population.

Authors:  Zhijie Han; Jiaojiao Qu; Jiehong Zhao; Xiao Zou
Journal:  Sci Rep       Date:  2018-07-23       Impact factor: 4.379

4.  Relation of plasma β-amyloid, clusterin, and tau with cerebral microbleeds: Framingham Heart Study.

Authors:  José Rafael Romero; Serkalem Demissie; Alexa Beiser; Jayandra J Himali; Charles DeCarli; Daniel Levy; Sudha Seshadri
Journal:  Ann Clin Transl Neurol       Date:  2020-06-26       Impact factor: 4.511

5.  ApoA-I deficiency increases cortical amyloid deposition, cerebral amyloid angiopathy, cortical and hippocampal astrogliosis, and amyloid-associated astrocyte reactivity in APP/PS1 mice.

Authors:  Emily B Button; Guilaine K Boyce; Anna Wilkinson; Sophie Stukas; Arooj Hayat; Jianjia Fan; Brennan J Wadsworth; Jerome Robert; Kris M Martens; Cheryl L Wellington
Journal:  Alzheimers Res Ther       Date:  2019-05-13       Impact factor: 6.982

Review 6.  HDL from an Alzheimer's disease perspective.

Authors:  Emily B Button; Jérôme Robert; Tara M Caffrey; Jianjia Fan; Wenchen Zhao; Cheryl L Wellington
Journal:  Curr Opin Lipidol       Date:  2019-06       Impact factor: 4.776

7.  Comparison of Plasma Lipoprotein Composition and Function in Cerebral Amyloid Angiopathy and Alzheimer's Disease.

Authors:  Anna Bonaterra-Pastra; Sofia Fernández-de-Retana; Andrea Rivas-Urbina; Núria Puig; Sònia Benítez; Olalla Pancorbo; David Rodríguez-Luna; Francesc Pujadas; Maria Del Mar Freijo; Silvia Tur; Maite Martínez-Zabaleta; Pere Cardona Portela; Rocío Vera; Lucia Lebrato-Hernández; Juan F Arenillas; Soledad Pérez-Sánchez; Joan Montaner; Jose Luis Sánchez-Quesada; Mar Hernández-Guillamon
Journal:  Biomedicines       Date:  2021-01-12

Review 8.  Genetic architecture of common non-Alzheimer's disease dementias.

Authors:  Rita Guerreiro; Elizabeth Gibbons; Miguel Tábuas-Pereira; Celia Kun-Rodrigues; Gustavo C Santo; Jose Bras
Journal:  Neurobiol Dis       Date:  2020-05-19       Impact factor: 5.996

9.  Association of clusterin with the BRI2-derived amyloid molecules ABri and ADan.

Authors:  Agueda Rostagno; Miguel Calero; Janice L Holton; Tamas Revesz; Tammaryn Lashley; Jorge Ghiso
Journal:  Neurobiol Dis       Date:  2021-07-21       Impact factor: 7.046

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.